| Market Cap | 4.22M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -767.84k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -38.00% |
| Sales | 1.95M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -70.00% |
| Dividend | N/A | Price/Book | 0.21 | EPS next 5Y | - | 52W High Chg | -91.00% |
| Recommedations | - | Quick Ratio | 5.33 | Shares Outstanding | 831.24M | 52W Low Chg | 6.00% |
| Insider Own | 3.12% | ROA | -2.96% | Shares Float | 798.07M | Beta | 5.02 |
| Inst Own | 7.46% | ROE | -1.77% | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | -40.50% | Profit Margin | -39.41% | Avg. Volume | 1,102,432 | Target Price | - |
| Oper. Margin | -16.73% | Earnings Date | - | Volume | 496,176 | Change | -2.86% |
Livento Group, Inc. engages in the film and television production business. It is also involved in the artificial intelligence and machine learning technology business; development and licensing of Elisee, a software product that can capture data and create predictive behavior based on client inputs that assist the client in establishing its investment portfolio; and real estate finance and development activities. The company was formerly known as NuGene International, Inc. and changed its name to Livento Group, Inc. in June 2022. Livento Group, Inc. is headquartered in New York, New York.
